A breakthrough in the mental health field as the Feel Program quantifies COVID-19’s Impact on Our Mental Health for the First Time
San Francisco, May 7, 2020 – For the first time in the mental health industry, Feel Therapeutics has used objective data collected from physiological signals detected by their proprietary Feel Emotion Sensor, an emotion tracking wearable device, to understand and quantify the changes to the emotional states of a sample group of participants in Europe and the USA. Results from this recent study showed sudden and significant changes to those physiological signals, indicating that emotional changes or new emotions were being experienced.
Over the course of eight weeks, between February and April 2020, Feel collected data from a random sample group of participants in Europe and the USA, and analysed 128 million electro-dermal activity (EDA) samples, 400 million heart rate variability (HRV) samples, 64 million skin temperature (ST) samples, and approximately 900 significant emotional moments.
Analysis of the data showed:
"The Feel Emotion Sensor was developed following many years of research, it uses proprietary algorithms and artificial intelligence to analyze physiological data to detect the emotional space, and is connected to a companion app and a data driven coaching and self-managment program. The introduction of this tool is a breakthrough in the mental health care space, which has been fairly subjective until now. It gives users real-time self awareness and tools to manage their emotions, and our therapists can use data to design personalized treatments. We are only scratching the surface of the potential of our technology and this will completely reinvent mental health care for the future,” says CTO and Co-Founder Haris Tsirmpas.
Feel Therapeutics, Inc. is developing Digital Biomarkers and Therapeutics to bring objective data and measurement in the way we diagnose, manage, and care for Mental Health. The company is backed by top-tier investors (Felicis, Anthemis, SOSV) and has partnerships with large pharmaceutical companies to develop novel digital biomarkers and bring digital health solutions to market as standalone programs or alongside medications. Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe. For more information, visit http://www.feeltherapeutics.com or contact us at firstname.lastname@example.org.